Article Text
Abstract
People for and against direct-to-consumer (DTC) genomic tests are arguing around two issues: first, on whether an autonomy-based account can justify the tests; second, on whether the tests bring any personal utility. Bunnik et al, in an article published in this journal, were doubtful on the latter, especially in clinically irrelevant and uninterpretable sequences, and how far this claim could go in the justification. Here we argue that personal utility is inherent to DTC genomic tests and their results. We discuss Bunnik et al's account of personal utility and identify problems in its motivation and application. We then explore concepts like utility and entertainment which suggest that DTC genomic tests bring personal utility to their consumers, both in the motivation and the content of the tests. This points to an alternative account of personal utility which entails that entertainment value alone is adequate to justify DTC genomic tests, given appropriate strategies to communicate tests results with the consumers. It supports the autonomy-based justification of the test by showing that DTC genomic test itself stands as a valuable option and facilitates meaningful choice of the people.
- Genetic Screening/Testing
- Genetic Information
- Regulation
- Predictive Genetic Testing
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Personal utility in genomic testing: is there such a thing
- Direct - to - consumer genomics on the scales of autonomy
- Defining and managing incidental findings in genetic and genomic practice
- On the personal utility of Alzheimer ’s disease - related biomarker testing in the research context
- Regulating the advertising of genetic tests in Europe: a balancing act
- Impact of direct - to - consumer genomic testing at long term follow - up
- Do genomic tests enhance autonomy
- Direct - to - consumer pharmacogenomic testing is associated with increased physician utilisation
- GPs are advised to ignore genetic test results that have no clinical basis
- From proband to provider: is there an obligation to inform genetic relatives of actionable risks discovered through direct - to - consumer genetic testing